Biogen's High-Dose Nusinersen Shows Faster Neurodegeneration Slowing in SMA Study
Event summary
- Nature Medicine published results from Biogen's Phase 2/3 DEVOTE study showing high-dose nusinersen (50 mg/28 mg) slowed neurodegeneration faster than the 12 mg regimen in SMA patients.
- Treatment-naïve infants on high-dose nusinersen saw a 26.19-point improvement in motor function compared to a sham group.
- The high-dose regimen is approved in the EU and Japan, with a U.S. FDA decision expected by April 3, 2026.
- Safety profile of the high-dose regimen was consistent with the 12 mg regimen, with pneumonia and respiratory failure as the most common adverse events.
The big picture
Biogen's high-dose nusinersen study results position the company to potentially dominate the SMA treatment market with a more effective regimen. The faster reduction in neurodegeneration markers and improved motor function outcomes could set a new standard for SMA therapy, though regulatory and competitive dynamics will shape its ultimate market impact.
What we're watching
- Regulatory Approval
- Whether the FDA will approve the high-dose nusinersen regimen by the April 3, 2026 PDUFA date, potentially expanding treatment options for SMA patients in the U.S.
- Market Competition
- How Biogen's high-dose nusinersen will compete with other SMA treatments, particularly in terms of efficacy and pricing.
- Commercialization Strategy
- The pace at which Biogen can transition existing SMA patients from the 12 mg regimen to the high-dose regimen, given the improvements seen in motor function.
Related topics